Serafin Andrew 4/A
4/A · Harmony Biosciences Holdings, Inc. · Filed Sep 4, 2020
Insider Transaction Report
Form 4/AAmended
Serafin Andrew
CHIEF STRATEGY OFFICER
Transactions
- Conversion
Series A Preferred Stock
2020-08-21−200,000→ 0 total→ Common Stock (27,039.05 underlying) - Conversion
Series C Preferred Stock
2020-08-21−51,021→ 0 total→ Common Stock (6,653.98 underlying) - Conversion
Common Stock
2020-08-21+33,693→ 33,693 total
Footnotes (3)
- [F1]Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash.
- [F2]Includes 2,693.34 shares of common stock received upon the payment of an in-kind dividend on the Series A Preferred Stock on August 21, 2020.
- [F3]Includes 443.27 shares of common stock received upon the payment of an in-kind dividend on the Series C Preferred Stock on August 21, 2020.